Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
This study suggests that the DDC NPs possess noteworthy potential as prospects for the development of PCA clinical chemotherapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Drugs & Pharmacology | Nanotechnology | Prostate Cancer | Study | Taxotere | Toxicology